摘要
目的:观察吉西他滨单药治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和毒副作用。方法:35例65岁以上NSCLC患者均接受国产吉西他滨(泽菲)800～1000mg/m2,第1、8天静脉滴注,每21～28天为1个周期,至少2个周期。结果:35例患者均可评价疗效,其中,完全缓解0例,部分缓解8例,有效率为22.86%(8/35)。中位疾病进展时间(TTP)为5.2个月,中位生存期为7.2个月,1年生存率为28.6%。主要毒副作用为白细胞及血小板下降,多为Ⅰ～Ⅲ度,可以耐受。结论:吉西他滨单药治疗老年晚期NSCLC安全有效,不但延长患者的生存时间,且可改善生活质量,毒副作用可以耐受。
Objective： To observe the clinical efficacy and toxicity of Gemcitabine monotherapy in the treatment of elder advanced non-small cell lung cancer （NSCLC）. Methods： 35 patients aged over 65 with advanced non-small cell lung cancer received Gemcitabine 800-1 000 mg/m^2 on d1,8 intravenously. Repeated every 21-28 days and with at least 2 cycles. Results： In the 35 evaluable cases CR was observed in 0 case and PR 8 cases ,the total response rate was 22.86% （8/35）, Median time to progression （TTP） of all the patients was 5.2 months, median survival time was 7.2 months and 1 year suruival rate was 28.6%. The main toxicities were leucopenia and thrombocytopenia, but the most were grade Ⅰ -Ⅲ. They were tolerable. Conclusion： Gemcitabine monotherapy is effective and safe in the treatment of elder advanced NSCLC. It prolong the survival time and improve the quality of life in patients with NSCLC. The toxieitits were well tolerated.
出处
《中国医药导报》
CAS
2009年第13期99-100,共2页
China Medical Herald
